E6 Vanguard Program - Strategy Lab - Barcelona Edition

Purpose & Context

The Barcelona Strategy Lab is one of five city roundtables in the E6 Concord Six Labs Program, run by the World Technology Congress under the Sovereign Vanguard initiative. E6 Concord (by WTC 2027) proposes major EU capital and sovereignty instruments, considering the official E6 Pillars, including a pan-European Savings & Investments Union; but currently lacks structured, first-hand evidence from the SMEs these instruments are meant to serve. Barcelona runs as a single-industry format, concentrating on Biotech, Healthcare & Pharma given the depth of the local BioRegion ecosystem.


Through this Lab initiative, WTC will generate evidence-based findings that will contribute to the Sovereignty Report to be presented to the European Investment Bank (EIB). This report will provide the EIB with a clearer understanding of the existing gaps, challenges, and support initiatives required for the region and the industry. Participating companies will have a unique opportunity to contribute directly to these findings and play a key role in shaping future recommendations and support mechanisms for the sector.

Institutional presence of the host city authority

Barcelona Investment Office / Barcelona City Council

Tuesday, 13 October 2026

13:00 - 16:00

Format: 2.5 hour Working Lunch
13:00

Welcome, warm intros & Pre-assigned seating

Framing: E6 Session narrative & session focus

priority threads: Capital Gap, Regulatory Fragmentation/US Market Entry, Cross-Border Scaling with a parallel track run.

Break. Facilitators consolidate scores across pods.

Plenary synthesis: aggregated findings presented, then a moderated fireside with AffirmedRX responding live.

Closing: one named, public ask per pod, recorded on the spot.

Close

Agenda

Objectives

RSVP

Methodology & Comparability

Friction point What it covers
1. Capital Access Financing gaps, ticket sizes, risk appetite, access to later-stage capital.
2. Regulatory Fragmentation Duplicative approvals, certification, export/dual-use classification, compliance cost.
3. Talent Ability to recruit, retain and relocate skilled technical and commercial talent.
4. Anchor-Corporate / Procurement Access Ability to sell to large industrial or public-sector buyers.
5. Cross-Border Scaling Barriers to expanding products, operations or infrastructure across markets.
Score Label Quick anchor
1 Negligible Mentioned, no material effect in last 24 months.
2 Minor Delay/cost but no strategy change (<1 month, <€50k).
3 Moderate Forced a change in strategy/timeline/market (1-6 months, €50k-€500k).
4 Severe Blocked a specific funding round, contract, hire, or market entry.
5 Structural Existential/repeated constraint; company would relocate or has.

Allocated Seats for Strategy Lab

1 seat per company | including confirmed & TBC participants

Sanofi Lukemia Research Institute Oryzon Barcelona City Council
IRTA Sequentia Biotech Braingaze Inbrain Neuroelectronics
bpsynergies.eu Aelix Therapeutics BioNext Consulting HAY pharma AG
Esteve Ferrer Reig Jofre Inbiomotion
Aortyx Pangaea Oncology Devicare MiMARK
Iproteos S.L. - merged Vall d'Hebron Inst. of Oncology Oxolife S.L. Telomere Therapeutics S.L.
IrsiCaixa / Aelix Therapeutics Aelix Therapeutics S.L. Leukos Biotech S.L. IRTA-CReSA
IBEC (Inst. Bioengineering of Cat.) Valentia BioPharma S.L.    

FAQ


About the Program

For SME / Company Participants

For Investors & Ecosystem Participants